Illumina Ventures Leads €16M Series A Investment in Digital PCR Firm Stilla Technologies
Stilla Technologies announced today that it has completed a €16 million ($18.3 million) Series A financing round led by Illumina Ventures.
Kurma Partners, LBO France, BNP Paribas Développement, Paris Saclay Seeds, and Idinvest Partners also participated in the round.
Stilla said it will use the funds to commercialize its Naica digital PCR system and to develop clinical applications. Specifically, the firm will aim to accelerate sales of Naica, launch a second-generation solution, and begin the process of clinically validating panels to be run on the system, with an initial focus in oncology, Stilla Cofounder and CEO Rémi Dangla said in a statement.